title: Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: a role for lymphocytes in ischemic brain injury?
abstract: OBJECTIVE
  Breakdown of the blood-brain barrier during stroke allows central nervous system antigens to leak into the systemic circulation and allows circulating leukocytes access to the brain. Encounter of central nervous system antigens by the peripheral immune system can be capitalized on to modulate the postischemic inflammatory response and potentially improve outcome from stroke.
  
  
  METHODS
  Male Lewis rats were tolerized to myelin basic protein (MBP) or ovalbumin (OVA) and subjected to 3 hours of middle cerebral artery occlusion (MCAO) or used as splenocyte donors for immunologically naive animals undergoing MCAO. Infarct size was determined at 24 hours by 2,3,5-triphenyltetrazolium chloride staining. In separate studies, mononuclear cells were removed from the brains of animals after MCAO for enzyme-linked immunospot (ELISPOT) assay and flow cytometry.
  
  
  RESULTS
  Median infarct volume in animals tolerized to MBP and those receiving splenocytes from MBP-tolerized donors was less than in animals tolerized to OVA and those receiving splenocytes from OVA-tolerized donors (87.7+/-54.9 versus 148+/-61.6 mm3 [P=0.01] and 89.2+/-77.5 versus 153+/-77.1 mm3 [P=0.05], respectively). There was an increase in the number of transforming growth factor-beta1-secreting mononuclear cells in MBP-tolerized animals undergoing sham surgery (P=0.001) as well as in ischemic animals 48 hours (P=0.02) and 336 hours (P=0.04) after stroke. A distinct subset of gammadelta T cells was present in the brains of MBP-tolerized but not control animals after stroke.
  
  
  CONCLUSIONS
  Immunologic tolerance and its neuroprotective effects can be transferred to naive animals and appear to be related to antigen-specific induction of transforming growth factor-beta1.
authors.affiliation: Department of Neurology, University of Washington School of Medicine, Harborview Medical Center, Seattle, WA 98104-2499, USA. kjb@u.washington.edu
authors.forename: Kyra
authors.initials: K
authors.lastname: Becker
authors.forename: Darin
authors.initials: D
authors.lastname: Kindrick
authors.forename: Richard
authors.initials: R
authors.lastname: McCarron
authors.forename: John
authors.initials: J
authors.lastname: Hallenbeck
authors.forename: Robert
authors.initials: R
authors.lastname: Winn
mesh_terms: D000281:Administration, Intranasal; D019264:Adoptive Transfer; D000818:Animals; D002545:Brain Ischemia / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D002452:Cell Count; D002544:Cerebral Infarction / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D019610:Cytoprotection / Q000276:immunology; D018450:Disease Progression; D007108:Immune Tolerance / Q000276:immunology*; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology / Q000502:physiology; D008297:Male; D004676:Myelin Basic Protein / Q000008:administration & dosage / Q000276:immunology*; D009297:Nasal Mucosa / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation*
chemical_list: D004676:Myelin Basic Protein